Testolone (RAD 140)

What Is Zyvex Pharma Testolone (RAD 140)

Zyvex Pharma Testolone (RAD 140) is a non-steroidal selective androgen receptor modulator (SARM) that has emerged as the most anabolically potent research compound in its class—a molecule originally developed by Radius Health as a potential treatment for breast cancer and muscle wasting conditions. Unlike traditional anabolic steroids that flood the entire body with androgenic activity, SARMs like Zyvex Rad 140 are designed to selectively target androgen receptors in muscle and bone tissue while minimizing effects on secondary organs like the prostate and scalp. Zyvex Pharma Testolone represents the most successful expression of this tissue-selective philosophy, delivering anabolic activity that rivals low-dose testosterone while maintaining a remarkably clean androgenic profile.

What Makes Zyvex Pharma Testolone Unique Among SARMs

Zyvex Pharma Testolone distinguishes itself from every other SARM through a combination of pharmacological properties that no competitor matches:

1. The Highest Anabolic-to-Androgenic Ratio in the Class:Zyvex Rad 140possesses an anabolic-to-androgenic ratio of approximately 90:1—meaning its muscle-building effects are 90 times more pronounced than its masculinizing effects. For comparison, Ligandrol (LGD-4033) ranges between 10:1 and >500:1 depending on the assay, while Ostarine (MK-2866) sits at approximately 3:1. This exceptional selectivity means users experience significant strength and lean mass gains with minimal risk of prostate enlargement, acne, or accelerated hair loss.
2. Clinical Trial Validation at Pharmaceutical Scale:Zyvex Pharma Testoloneis one of the few SARMs that has completed a first-in-human Phase 1 clinical trial. In a study of 22 heavily pretreated patients with ER+/HER2- metastatic breast cancer, RAD 140 was administered at doses ranging from 50 mg to 150 mg daily. The trial established a half-life of 44.7 hours, supporting once-daily dosing, and identified a maximum tolerated dose of 100 mg/day. The most frequent treatment-emergent adverse events were elevated AST (59.1%), ALT (45.5%), and total bilirubin (27.3%)—hepatotoxicity signals that have been consistently observed in RAD 140 research.
3. Half-Life That Redefines Dosing Convenience:At approximately 44 hours, Zyvex Rad 140's half-life is among the longest of any orally administered SARM. This pharmacokinetic profile allows for once-daily dosing with remarkably stable blood plasma levels, eliminating the peaks and troughs that characterize shorter-acting compounds. For users transitioning from injectable anabolics, this stability feels familiar; for those new to performance enhancement, it simplifies protocol adherence.
4. Non-Aromatizing and Non-5α-Reducible:Zyvex Pharma Testolonedoes not convert to estrogen through the aromatase enzyme and is not a substrate for 5-alpha-reductase. This means no gynecomastia risk, no water retention from estrogenic activity, and no conversion to DHT that would threaten the hairline. Users who are finasteride-sensitive or genetically predisposed to male pattern baldness often tolerate Zyvex Pharma Testolone better than testosterone on the scalp.

Zyvex Pharma Testolone (RAD 140) Cycle Guide

Zyvex Pharma Testolone is administered orally. The compound has a half-life of approximately 44 hours, with peak plasma concentrations reached at approximately 1.5 hours post-dose and active effects persisting for up to 48 hours.

Standard Dosage:

• Beginner:10 mg daily
• Intermediate:15 mg to 20 mg daily
• Advanced:20 mg to 30 mg daily
• Maximum Recommended:30 mg daily

Cycle Duration:

• Recommended:6 to 8 weeks
• Maximum:12 weeks

Administration Protocol:

• Take once daily at approximately the same time each day
• Can be taken with or without food
• Liquid suspension is the most common research format; oral bioavailability is approximately 50%

The "Enhanced First Cycle" Application:

Zyvex Rad 140 has become the definitive choice for users seeking their first oral "enhanced" cycle without needles. Its anabolic potency at 15-20 mg daily approaches that of a mild testosterone cycle, while its non-aromatizing nature eliminates the estrogen management complexity that burdens traditional steroid users. The compound delivers three primary outcomes: rapid strength gains, lean mass accrual, and a distinct increase in training aggression and drive.

Synergistic Stacking Examples:

• The "Recomp" Stack:Zyvex Pharma Testolone 15 mg/day + Ostarine (MK-2866) 20 mg/day. Ostarine provides joint support and mild anabolic activity while Zyvex Rad 140 drives the heavy lifting for lean mass and strength.
• The "Lean Bulk" Stack:Zyvex Pharma Testolone 20 mg/day + Ibutamoren (MK-677) 20 mg/day. MK-677 stimulates growth hormone and appetite, while Zyvex Rad 140 ensures the additional calories are partitioned toward muscle rather than fat.
• The "Conditioning" Stack:Zyvex Pharma Testolone 15 mg/day + Cardarine (GW-501516) 20 mg/day. Cardarine enhances endurance and fat oxidation, complementing Zyvex Rad 140's strength and muscle-building effects.
• Crucial Note:Zyvex Pharma Testolone suppresses endogenous testosterone production and requires a full PCT. Liver support with TUDCA at 500 mg/day is strongly recommended, as hepatotoxicity is the most consistently reported adverse effect in both clinical and anecdotal data.

Post-Cycle Therapy (PCT)

Zyvex Pharma Testolone causes significant suppression of the Hypothalamic-Pituitary-Testicular Axis (HPTA). Despite being a SARM rather than a traditional steroid, Zyvex Rad 140 suppresses endogenous testosterone production "as hard as a mild AAS cycle" according to published protocol guidance. Post-cycle bloodwork typically reveals suppressed LH and FSH with total testosterone dropping below baseline.

The 44-Hour Half-Life Consideration:

Zyvex Rad 140's extended half-life means the compound remains active in the system for several days after the last dose. While this provides stable on-cycle levels, it also means suppression persists well into the post-cycle window. PCT should begin the day after the last dose for most users, though some protocols recommend waiting 24 to 48 hours to allow initial clearance.

Common PCT Protocol:

• Tamoxifen (Nolvadex):20 mg daily for 4 weeks
• Enclomiphene:5 mg to 25 mg daily for 4 weeks (alternative to tamoxifen)
• Crucial Addition:Continue liver support (TUDCA 500 mg/day) through the PCT window, as Zyvex Pharma Testolone's hepatic stress does not resolve immediately upon discontinuation. Monitor liver function tests mid-cycle and drop the compound if AST/ALT exceed 3× the upper limit of normal.

Important Note: Zyvex Pharma Testolone should not be bridged into another cycle without a full recovery window. Unlike some compounds that allow for "bridging" protocols, Zyvex Rad 140's profound suppression demands complete HPTA restoration before any subsequent cycle is considered.

Potential Side Effects

Zyvex Pharma Testolone carries a side-effect profile that differs fundamentally from traditional anabolic steroids—no estrogenic effects, no DHT conversion, but significant hepatic and suppressive concerns.

Hepatotoxicity (The Primary Concern):

Zyvex Rad 140 is the SARM most consistently linked to liver enzyme elevation in both clinical trials and published case reports. In the Phase 1 breast cancer trial, 59.1% of patients experienced elevated AST and 45.5% experienced elevated ALT—the most frequent adverse events observed. These elevations were typically asymptomatic, occurred early in treatment, and were reversible upon dose reduction or discontinuation. However, the consistency of this signal across studies and case reports makes liver support and monitoring non-negotiable. Grade 3/4 liver enzyme elevations occurred in 22.7% of trial patients at doses of 50-150 mg/day.

HPTA Suppression:

Zyvex Pharma Testolone suppresses endogenous testosterone production through the same negative feedback mechanism as traditional androgens. Users should expect suppressed LH and FSH, reduced total testosterone, and the associated symptoms of low testosterone—lethargy, reduced libido, and mood changes—if PCT is inadequate.

Lipid Profile Effects:

SARMs including Zyvex Rad 140 have been associated with reductions in HDL (good cholesterol). In related SARM research, HDL cholesterol decreased in a dose-dependent manner. Cardiovascular health monitoring through lipid panels is recommended.

Androgenic Side Effects (Minimal):

Due to Zyvex Pharma Testolone's exceptional tissue selectivity (90:1 anabolic-to-androgenic ratio), androgenic side effects are rare and mild. However, some users report increased aggression, irritability, and mood swings at higher doses—effects that may be related to central nervous system androgen receptor activation rather than peripheral androgenic activity.

Gastrointestinal Effects:

Nausea, vomiting, and decreased appetite have been reported, particularly at higher doses. In the clinical trial, vomiting and dehydration each occurred in 27.3% of patients at doses of 50-150 mg/day.

Red Flag Warnings:

Discontinue immediately and seek medical attention if you experience: persistent nausea with right upper quadrant abdominal pain; jaundice (yellowing of skin or eyes); dark urine or clay-colored stools; severe lethargy or fatigue that does not resolve with rest; or symptoms of acute liver injury.

• Mandatory Protocol:Bloodwork is non-negotiable. Monitor liver enzymes (AST/ALT), lipid panel (HDL/LDL), total testosterone, LH, and FSH at baseline, mid-cycle (week 4), and post-cycle.

Ready to experience the most anabolically potent SARM available? Secure your Zyvex Pharma Testolone (RAD 140) today and discover why it competes with low-dose testosterone—backed by our fast, discreet, and insured delivery.